Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 330

1.

Current Status and Trends in Alternative Models to Study Fungal Pathogens.

Junqueira JC, Mylonakis E.

J Fungi (Basel). 2019 Jan 26;5(1). pii: E12. doi: 10.3390/jof5010012.

2.

In uncomplicated acute appendicitis, 61% of patients initially treated with antibiotics had not had appendectomy at 5 years.

Kalligeros M, Mylonakis E.

Ann Intern Med. 2019 Jan 15;170(2):JC10. doi: 10.7326/ACPJC-2019-170-2-010. No abstract available.

PMID:
30641561
3.

Cross-Domain and Viral Interactions in the Microbiome.

Rowan-Nash AD, Korry BJ, Mylonakis E, Belenky P.

Microbiol Mol Biol Rev. 2019 Jan 9;83(1). pii: e00044-18. doi: 10.1128/MMBR.00044-18. Print 2019 Mar. Review.

4.

Anti-Candida albicans Activity of Thiazolylhydrazone Derivatives in Invertebrate and Murine Models.

Cruz LIB, Lopes LFF, de Camargo Ribeiro F, de Sá NP, Lino CI, Tharmalingam N, de Oliveira RB, Rosa CA, Mylonakis E, Fuchs BB, Johann S.

J Fungi (Basel). 2018 Dec 12;4(4). pii: E134. doi: 10.3390/jof4040134.

5.

The Cost-Effectiveness of Corticosteroids for the Treatment of Community-Acquired Pneumonia.

Pliakos EE, Andreatos N, Tansarli GS, Ziakas PD, Mylonakis E.

Chest. 2018 Nov 15. pii: S0012-3692(18)32727-2. doi: 10.1016/j.chest.2018.11.001. [Epub ahead of print]

PMID:
30448195
6.

Procalcitonin-guided antibiotic prescribing did not reduce antibiotic use in suspected LRTI in the ED.

Tansarli GS, Mylonakis E.

Ann Intern Med. 2018 Oct 16;169(8):JC39. doi: 10.7326/ACPJC-2018-169-8-039. No abstract available.

PMID:
30326083
7.

Vulnerability of long-term care facility residents to Clostridium difficile infection due to microbiome disruptions.

Fuchs BB, Tharmalingam N, Mylonakis E.

Future Microbiol. 2018 Oct;13:1537-1547. doi: 10.2217/fmb-2018-0157. Epub 2018 Oct 12. Review.

PMID:
30311778
8.

Reply to Burnham, Kakol, Vazquez-Guillamet.

Parente DM, Cunha CB, Mylonakis E, Timbrook TT.

Clin Infect Dis. 2018 Oct 10. doi: 10.1093/cid/ciy869. [Epub ahead of print] No abstract available.

PMID:
30304399
9.

Structure-activity relationships of pyrazole-4-carbodithioates as antibacterials against methicillin-resistant Staphylococcus aureus.

Majed H, Johnston T, Kelso C, Monachino E, Jergic S, Dixon NE, Mylonakis E, Kelso MJ.

Bioorg Med Chem Lett. 2018 Dec 1;28(22):3526-3528. doi: 10.1016/j.bmcl.2018.09.038. Epub 2018 Oct 3.

PMID:
30297281
10.

Galleria mellonella experimental model for bat fungal pathogen Pseudogymnoascus destructans and human fungal pathogen Pseudogymnoascus pannorum.

Fuchs BB, Chaturvedi S, Rossoni RD, de Barros PP, Torres-Velez F, Mylonakis E, Chaturvedi V.

Virulence. 2018;9(1):1539-1547. doi: 10.1080/21505594.2018.1518087.

11.

Discovery and Optimization of nTZDpa as an Antibiotic Effective Against Bacterial Persisters.

Kim W, Steele AD, Zhu W, Csatary EE, Fricke N, Dekarske MM, Jayamani E, Pan W, Kwon B, Sinitsa IF, Rosen JL, Conery AL, Fuchs BB, Vlahovska PM, Ausubel FM, Gao H, Wuest WM, Mylonakis E.

ACS Infect Dis. 2018 Nov 9;4(11):1540-1545. doi: 10.1021/acsinfecdis.8b00161. Epub 2018 Aug 28.

PMID:
30132650
12.

SDH2 is involved in proper hypha formation and virulence in Candida albicans.

Bi S, Lv QZ, Wang TT, Fuchs BB, Hu DD, Anastassopoulou CG, Desalermos A, Muhammed M, Wu CL, Jiang YY, Mylonakis E, Wang Y.

Future Microbiol. 2018 Aug;13:1141-1156. doi: 10.2217/fmb-2018-0033. Epub 2018 Aug 16.

PMID:
30113213
13.

Pathogenesis of the Candida parapsilosis Complex in the Model Host Caenorhabditis elegans.

Souza ACR, Fuchs BB, Alves VS, Jayamani E, Colombo AL, Mylonakis E.

Genes (Basel). 2018 Aug 8;9(8). pii: E401. doi: 10.3390/genes9080401.

14.

A phenylthiazole derivative demonstrates efficacy on treatment of the cryptococcosis & candidiasis in animal models.

Sá NP, Lima CM, A Dos Santos JR, Costa MC, de Barros PP, Junqueira JC, Vaz JA, Oliveira RB, Fuchs BB, Mylonakis E, Rosa CA, Santos DA, Johann S.

Future Sci OA. 2018 Apr 25;4(6):FSO305. doi: 10.4155/fsoa-2018-0001. eCollection 2018 Jul.

15.

Butenafine and analogues: An expeditious synthesis and cytotoxicity and antifungal activities.

Porras AMG, Terra BS, Braga TC, Magalhães TFF, Martins CVB, da Silva DL, Baltazar LM, Gouveia LF, de Freitas GJC, Santos DA, Resende-Stoianoff MA, Fuchs BB, Mylonakis E, de Freitas RP, de Fátima Â.

J Adv Res. 2018 Jun 21;14:81-91. doi: 10.1016/j.jare.2018.06.004. eCollection 2018 Nov.

16.

Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults.

Tansarli GS, Mylonakis E.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00635-18. doi: 10.1128/AAC.00635-18. Print 2018 Sep.

PMID:
29987137
17.

The Cost-effectiveness of Antimicrobial Lock Solutions for the Prevention of Central Line-Associated Bloodstream Infections.

Pliakos EE, Andreatos N, Ziakas PD, Mylonakis E.

Clin Infect Dis. 2019 Jan 18;68(3):419-425. doi: 10.1093/cid/ciy511.

PMID:
29945237
18.

Galleria mellonella as a model invertebrate host for the study of muriform cells of dematiaceous fungi.

Huang X, Liu Y, Xi L, Zeng K, Mylonakis E.

Future Microbiol. 2018 Jul;13:1021-1028. doi: 10.2217/fmb-2018-0036. Epub 2018 Jun 21.

PMID:
29927339
19.

Medicare part D prescribing for direct oral anticoagulants in the United States: Cost, use and the "rubber effect".

Ziakas PD, Kourbeti IS, Poulou LS, Vlachogeorgos GS, Mylonakis E.

PLoS One. 2018 Jun 7;13(6):e0198674. doi: 10.1371/journal.pone.0198674. eCollection 2018.

20.

Antifungal activity directed toward the Cell wall by 2-cyclohexylidenhydrazo-4-phenyl-thiazole against Candida albicans.

de Sa NP, Possa AP, Perez P, Ferreira JMS, Fonseca NC, Lino CI, Cruz LB, de Oliveira RB, Rosa CA, Borelli BM, Mylonakis E, Fuchs BB, Johann S.

Infect Disord Drug Targets. 2018 May 30. doi: 10.2174/1871526518666180531101605. [Epub ahead of print]

PMID:
29852876
21.

The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship.

Pliakos EE, Andreatos N, Shehadeh F, Ziakas PD, Mylonakis E.

Clin Microbiol Rev. 2018 May 30;31(3). pii: e00095-17. doi: 10.1128/CMR.00095-17. Print 2018 Jul. Review.

PMID:
29848775
22.

Influence of subinhibitory concentrations of NH125 on biofilm formation & virulence factors of Staphylococcus aureus.

Liu Q, Zheng Z, Kim W, Burgwyn Fuchs B, Mylonakis E.

Future Med Chem. 2018 Jun 1;10(11):1319-1331. doi: 10.4155/fmc-2017-0286. Epub 2018 May 30.

PMID:
29846088
23.

Use of T2MR in invasive candidiasis with and without candidemia.

Zacharioudakis IM, Zervou FN, Mylonakis E.

Future Microbiol. 2018 Aug;13:1165-1173. doi: 10.2217/fmb-2018-0079. Epub 2018 May 24. Review.

PMID:
29792512
24.

Propyl-5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate (HMPC): a new bacteriostatic agent against methicillin-resistant Staphylococcus aureus.

Johnston T, Van Tyne D, Chen RF, Fawzi NL, Kwon B, Kelso MJ, Gilmore MS, Mylonakis E.

Sci Rep. 2018 May 4;8(1):7062. doi: 10.1038/s41598-018-25571-w.

25.

In vivo and in vitro activity of a bis-arylidenecyclo-alkanone against fluconazole-susceptible and -resistant isolates of Candida albicans.

de Sá NP, de Paula LFJ, Lopes LFF, Cruz LIB, Matos TTS, Lino CI, de Oliveira RB, de Souza-Fagundes EM, Fuchs BB, Mylonakis E, Johann S.

J Glob Antimicrob Resist. 2018 Sep;14:287-293. doi: 10.1016/j.jgar.2018.04.012. Epub 2018 Apr 30.

PMID:
29715565
26.

The impact of antibiotic prescription rates on the incidence of MRSA bloodstream infections: A county-level, US-wide analysis.

Andreatos N, Shehadeh F, Pliakos EE, Mylonakis E.

Int J Antimicrob Agents. 2018 Aug;52(2):195-200. doi: 10.1016/j.ijantimicag.2018.04.003. Epub 2018 Apr 12.

PMID:
29656062
27.

T2 Magnetic Resonance Assay: Overview of Available Data and Clinical Implications.

Zacharioudakis IM, Zervou FN, Mylonakis E.

J Fungi (Basel). 2018 Apr 4;4(2). pii: E45. doi: 10.3390/jof4020045. Review.

28.

Fecal Microbiome Among Nursing Home Residents with Advanced Dementia and Clostridium difficile.

Araos R, Andreatos N, Ugalde J, Mitchell S, Mylonakis E, D'Agata EMC.

Dig Dis Sci. 2018 Jun;63(6):1525-1531. doi: 10.1007/s10620-018-5030-7. Epub 2018 Mar 28.

PMID:
29594967
29.

A new class of synthetic retinoid antibiotics effective against bacterial persisters.

Kim W, Zhu W, Hendricks GL, Van Tyne D, Steele AD, Keohane CE, Fricke N, Conery AL, Shen S, Pan W, Lee K, Rajamuthiah R, Fuchs BB, Vlahovska PM, Wuest WM, Gilmore MS, Gao H, Ausubel FM, Mylonakis E.

Nature. 2018 Apr 5;556(7699):103-107. doi: 10.1038/nature26157. Epub 2018 Mar 28.

PMID:
29590091
30.

Candidemia in Adults at a Tertiary Hospital in China: Clinical Characteristics, Species Distribution, Resistance, and Outcomes.

Lin S, Chen R, Zhu S, Wang H, Wang L, Zou J, Yan J, Zhang X, Farmakiotis D, Tan X, Mylonakis E.

Mycopathologia. 2018 Aug;183(4):679-689. doi: 10.1007/s11046-018-0258-5. Epub 2018 Mar 23.

PMID:
29572768
31.

Strategies against methicillin-resistant Staphylococcus aureus persisters.

Kim W, Hendricks GL, Tori K, Fuchs BB, Mylonakis E.

Future Med Chem. 2018 Apr 1;10(7):779-794. doi: 10.4155/fmc-2017-0199. Epub 2018 Mar 23. Review.

PMID:
29569952
32.

Fecal transplant by oral capsule was noninferior to delivery by colonoscopy for C difficile recurrence.

Tansarli GS, Mylonakis E.

Ann Intern Med. 2018 Mar 20;168(6):JC31. doi: 10.7326/ACPJC-2018-168-6-031. No abstract available.

PMID:
29554669
33.

Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori.

Tharmalingam N, Port J, Castillo D, Mylonakis E.

Sci Rep. 2018 Feb 27;8(1):3701. doi: 10.1038/s41598-018-22037-x.

34.

Antibacterial Properties of Four Novel Hit Compounds from a Methicillin-Resistant Staphylococcus aureus-Caenorhabditis elegans High-Throughput Screen.

Tharmalingam N, Rajmuthiah R, Kim W, Fuchs BB, Jeyamani E, Kelso MJ, Mylonakis E.

Microb Drug Resist. 2018 Jun;24(5):666-674. doi: 10.1089/mdr.2017.0250. Epub 2018 Feb 20.

PMID:
29461939
35.

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).

Baddley JW, Cantini F, Goletti D, Gómez-Reino JJ, Mylonakis E, San-Juan R, Fernández-Ruiz M, Torre-Cisneros J.

Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S10-S20. doi: 10.1016/j.cmi.2017.12.025. Epub 2018 Feb 6. Review.

PMID:
29459143
36.

Lactobacillus paracasei 28.4 reduces in vitro hyphae formation of Candida albicans and prevents the filamentation in an experimental model of Caenorhabditis elegans.

de Barros PP, Scorzoni L, Ribeiro FC, Fugisaki LRO, Fuchs BB, Mylonakis E, Jorge AOC, Junqueira JC, Rossoni RD.

Microb Pathog. 2018 Apr;117:80-87. doi: 10.1016/j.micpath.2018.02.019. Epub 2018 Feb 9.

PMID:
29432910
37.

Antifungal activity of clinical Lactobacillus strains against Candida albicans biofilms: identification of potential probiotic candidates to prevent oral candidiasis.

Rossoni RD, de Barros PP, de Alvarenga JA, Ribeiro FC, Velloso MDS, Fuchs BB, Mylonakis E, Jorge AOC, Junqueira JC.

Biofouling. 2018 Feb;34(2):212-225. doi: 10.1080/08927014.2018.1425402. Epub 2018 Jan 30.

PMID:
29380647
38.

Efficacy of T2 Magnetic Resonance Assay in Monitoring Candidemia after Initiation of Antifungal Therapy: the Serial Therapeutic and Antifungal Monitoring Protocol (STAMP) Trial.

Mylonakis E, Zacharioudakis IM, Clancy CJ, Nguyen MH, Pappas PG.

J Clin Microbiol. 2018 Mar 26;56(4). pii: e01756-17. doi: 10.1128/JCM.01756-17. Print 2018 Apr.

39.
40.

Antimicrobial activity of 1,3,4-oxadiazole derivatives against planktonic cells and biofilm of Staphylococcus aureus.

Zheng Z, Liu Q, Kim W, Tharmalingam N, Fuchs BB, Mylonakis E.

Future Med Chem. 2018 Feb;10(3):283-296. doi: 10.4155/fmc-2017-0159. Epub 2018 Jan 15.

41.

Inappropriate Management of Asymptomatic Patients With Positive Urine Cultures: A Systematic Review and Meta-analysis.

Flokas ME, Andreatos N, Alevizakos M, Kalbasi A, Onur P, Mylonakis E.

Open Forum Infect Dis. 2017 Nov 20;4(4):ofx207. doi: 10.1093/ofid/ofx207. eCollection 2017 Fall.

42.

Correlation of Opioid Mortality with Prescriptions and Social Determinants: A Cross-sectional Study of Medicare Enrollees.

Grigoras CA, Karanika S, Velmahos E, Alevizakos M, Flokas ME, Kaspiris-Rousellis C, Evaggelidis IN, Artelaris P, Siettos CI, Mylonakis E.

Drugs. 2018 Jan;78(1):111-121. doi: 10.1007/s40265-017-0846-6. Review.

PMID:
29159797
43.

Histone acetyltransferase encoded by NGG1 is required for morphological conversion and virulence of Candida albicans.

Li DD, Fuchs BB, Wang Y, Huang XW, Hu DD, Sun Y, Chai D, Jiang YY, Mylonakis E.

Future Microbiol. 2017 Dec;12:1497-1510. doi: 10.2217/fmb-2017-0084. Epub 2017 Nov 7.

PMID:
29110536
44.

Triple therapy reduced mortality more than oseltamivir alone in patients admitted for severe influenza infection.

Andreatos N, Mylonakis E.

Ann Intern Med. 2017 Oct 17;167(8):JC41. doi: 10.7326/ACPJC-2017-167-8-041. No abstract available.

PMID:
29049760
45.

Agrobacterium tumefaciens-mediated transformation: an efficient tool for targeted gene disruption in Talaromyces marneffei.

Xiao X, Feng J, Li Y, Chen Z, Shi M, Xi L, Mylonakis E, Zhang J.

World J Microbiol Biotechnol. 2017 Sep 25;33(10):183. doi: 10.1007/s11274-017-2352-0.

PMID:
28948456
46.

The salivary microbiome is consistent between subjects and resistant to impacts of short-term hospitalization.

Cabral DJ, Wurster JI, Flokas ME, Alevizakos M, Zabat M, Korry BJ, Rowan AD, Sano WH, Andreatos N, Ducharme RB, Chan PA, Mylonakis E, Fuchs BB, Belenky P.

Sci Rep. 2017 Sep 8;7(1):11040. doi: 10.1038/s41598-017-11427-2.

47.

An Intestine-Derived Neuropeptide Controls Avoidance Behavior in Caenorhabditis elegans.

Lee K, Mylonakis E.

Cell Rep. 2017 Sep 5;20(10):2501-2512. doi: 10.1016/j.celrep.2017.08.053.

48.

The impact of HIV infection and socioeconomic factors on the incidence of gonorrhea: A county-level, US-wide analysis.

Andreatos N, Grigoras C, Shehadeh F, Pliakos EE, Stoukides G, Port J, Flokas ME, Mylonakis E.

PLoS One. 2017 Sep 1;12(9):e0183938. doi: 10.1371/journal.pone.0183938. eCollection 2017.

49.

Urinary tract infections caused by ESBL-producing Enterobacteriaceae in renal transplant recipients: A systematic review and meta-analysis.

Alevizakos M, Nasioudis D, Mylonakis E.

Transpl Infect Dis. 2017 Dec;19(6). doi: 10.1111/tid.12759. Epub 2017 Oct 24. Review.

PMID:
28803446
50.

Extended-spectrum β-lactamase-producing Enterobacteriaceae colonisation in long-term care facilities: a systematic review and meta-analysis.

Flokas ME, Alevizakos M, Shehadeh F, Andreatos N, Mylonakis E.

Int J Antimicrob Agents. 2017 Nov;50(5):649-656. doi: 10.1016/j.ijantimicag.2017.08.003. Epub 2017 Aug 3. Review.

PMID:
28782707

Supplemental Content

Loading ...
Support Center